Heat Biologics, Inc. (NASDAQ:HTBX)’s share price traded down 9.3% during mid-day trading on Thursday . The stock traded as low as $0.38 and last traded at $0.39. 579,900 shares changed hands during trading, a decline of 4% from the average session volume of 603,963 shares. The stock had previously closed at $0.43.
Separately, Griffin Securities started coverage on Heat Biologics in a research report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $2.13.
Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. The firm had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.50 million. equities research analysts anticipate that Heat Biologics, Inc. will post -0.38 earnings per share for the current fiscal year.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.